Allergy & Immunology
COHORT
● Cohort
Same-day desensitization linked to lower breakthrough reaction rate than rapid protocol in chemotherapy hypersensitivity
Frontiers in Medicine
Published April 1, 2026
DOI ↗
This retrospective cohort study compared two desensitization protocols in 120 patients who experienced hypersensitivity reactions to platinum- or taxane-based chemotherapy. The study analyzed 76 patients undergoing rapid drug desensitization (RDD) and 44 patients undergoing same-day desensitization (SDD), reviewing medical records to assess breakthrough reaction (BTR) rates.
The primary outcome was breakthrough reaction rate. The RDD group experienced a 24% BTR rate across 406 desensitizations, while the SDD group experienced a 15% BTR rate across 164 desensitizations. The analysis indicated a 14.6-point reduction in the probability of BTR with SDD compared to RDD, though no p-values or confidence intervals were reported for this effect.
Safety data focused on breakthrough reactions, which occurred in both groups. The authors described desensitization procedures as safe and effective overall, though serious adverse events and discontinuation rates were not reported. Key limitations include the retrospective design and reliance on medical record review, which may introduce selection bias and unmeasured confounding.
For practice, this study suggests SDD may be associated with fewer breakthrough reactions than RDD in patients with hypersensitivity to platinum or taxane chemotherapy. However, the retrospective nature and lack of statistical precision measures mean these findings should be interpreted cautiously. Desensitization procedures remain important for allowing continuation of first-line chemotherapy after hypersensitivity reactions, but protocol selection should consider individual patient factors and institutional experience.
Imagine facing a life-saving cancer drug, only to have a severe allergic reaction to it. For patients on platinum or taxane chemotherapy, this can mean stopping the most effective treatment. Doctors use desensitization protocols—carefully controlled, slow infusions—to help the body tolerate the drug. The big question is: which protocol works better to prevent another reaction during treatment?
A review of medical records for 120 patients compared two approaches. One group received a rapid drug desensitization (RDD) protocol. The other received a same-day desensitization (SDD) protocol, where the process is completed in a single day. The key finding was that the same-day group had a lower rate of 'breakthrough reactions'—allergic symptoms that occur despite the desensitization procedure. Specifically, 15% of desensitizations in the same-day group had a breakthrough reaction, compared to 24% in the rapid protocol group. The analysis estimated the same-day protocol reduced the probability of a reaction.
It's important to understand what this study does and doesn't tell us. The researchers looked back at existing patient records, which means they couldn't control how patients were chosen for each protocol. We don't know the exact statistical strength of the finding, as p-values or confidence intervals weren't reported. The study also confirms that these procedures, while carrying the risk of a breakthrough reaction, are a safe and effective way to let crucial cancer treatment continue. The takeaway is a promising signal that deserves a closer, more controlled look in future research.
What this means for you: A same-day desensitization protocol may help reduce allergic reactions during critical chemotherapy.
View Original Abstract ↓
BackgroundRapid drug desensitization (RDD) allows first-line treatment to continue after a hypersensitivity reaction to the antineoplastic agent. There are different desensitization procedures, and none of them are free from breakthrough reactions (BTR).ObjectivesThe objective of the study is to evaluate and compare the efficacy of different desensitization procedures, considering the effect of a series of confounding variables, and to describe the characteristics of BTRs in different procedures.MethodsA retrospective, comparative review of medical records from patients who experienced hypersensitivity reactions to platinum- or taxane-based chemotherapy was conducted. Patients were categorized into two groups; rapid drug desensitization (RDD) and same-day desensitization (SDD), according to the intervention performed on the day of the initial reaction. Demographic data, drug, retreatment, cancer type, phenotype and severity of the initial reaction, allergy testing, number of desensitizations performed, outcome of desensitizations, and number, phenotype and severity of BTRs were recorded according to group.ResultsIn the RDD group, 406 desensitizations were analyzed in 76 subjects with a BTR rate of 24%. In the SDD group, 164 desensitizations were analyzed in 44 subjects with a BTR rate of 15%. A marginaleffects analysis using a Bayesian hierarchical model showed a 14.6-point reduction in the probability of BTR in the SDD group.ConclusionThis study confirms that desensitization procedures are safe and effective and allows us to conclude, based on the data and the model, that the SDD group has a lower probability of BTR than the RDD group.
